Ipsen – Half year statement – 2025 12 31

Core Viewpoint - Ipsen has provided a half-year statement regarding its liquidity agreement with NATIXIS ODDO BHF, detailing the resources allocated to the liquidity account as of December 31, 2025, and the trading volume executed during the second half of 2025 [1]. Group 1: Company Overview - Ipsen is a global biopharmaceutical company focused on transformative medicines in oncology, rare diseases, and neuroscience, with nearly 100 years of development experience [2]. - The company operates in over 40 countries and partners globally to deliver medicines to more than 100 countries [2]. Group 2: Financial Details - As of December 31, 2025, the liquidity account included resources amounting to €2,126,437.66 from 30,064 shares and €3,137,934.80 from 12,751 shares [6]. - The trading volume during the period from July 1, 2025, to December 31, 2025, included 384,725 shares purchased for €44,989,151.30 and 392,691 shares sold for €45,795,172 [6].